Follows adults with atrial fibrillation treated with the PulseSelect PFA System
Follows adults with atrial fibrillation who receive the PulseSelect PFA System.
Plain-language title generated from the registry record
Registry title: PulseSelect™ PFA Global Registry
Key facts
- Where
- Auckland, New ZealandSee the site
Where in New Zealand
- Auckland HospitalAuckland, New ZealandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medtronic Cardiac Ablation Solutions
- Trial code
- NCT06393920
- Record updated
- 16 October 2026
- Original description
The PulseSelect™ PFA Global Registry is a prospective, global, multi-center, observational post-approval study. Subjects will be treated with the PulseSelect™ PFA System and followed according to SOC.Read full original descriptionShow less
PulseSelect PFA Global Registry, a Part of the Medtronic Cardiac Ablation Post-Market Study Platform
The PulseSelect™ PFA Global Registry is a prospective, global, multi-center, observational post-approval study. Subjects will be treated with the PulseSelect™ PFA System and followed according to SOC.
Inclusion: Subject is ≥ 18 years of age or minimum age as required by local regulations; Subject has been diagnosed with atrial fibrillation (AF); Planned procedure using commercially available PulseSelect™ PFA System; Willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements.
Exclusion: Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager; Subject with exclusion criteria required by local law.